Clinical Trials Logo

Chikungunya Virus Infection clinical trials

View clinical trials related to Chikungunya Virus Infection.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04838444 Active, not recruiting - Clinical trials for Chikungunya Virus Infection

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)

Start date: April 2, 2021
Phase: Phase 3
Study type: Interventional

In this open-label Phase 3b, single arm study, persistence of antibodies and long term safety will be evaluated in up to 375 subjects rolled over from study VLA1553-301 (NCT number: NCT04546724).

NCT ID: NCT04441905 Active, not recruiting - Clinical trials for Chikungunya Virus Infection

Phase 1 Study of SAR440894 vs Placebo

Start date: October 14, 2020
Phase: Phase 1
Study type: Interventional

A single, ascending-dose design with five dose-cohorts of 8 subjects. Forty healthy adults aged 18 to 45, inclusive, will be recruited and admitted at multiple sites. Each subject will be randomized to receive either SAR440894 or matching placebo via 60-minute intravenous infusion. In each cohort of 8 subjects, the randomization ratio will be 6 active to 2 placebo, and 2 sentinel subjects (one from each active and placebo group) will be dosed first. Dosing of the next dose-cohort will be dependent on acceptable meeting predefined safety criteria in the preceding cohort. Each subject's participation will take place over approximately 150 days, not including the screening visit. There are no hypotheses for this phase I study. The primary objective will be to determine the safety of single ascending intravenous (IV) infusions of SAR440894 when administered in healthy adults.